[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339155-105":59,"doc-detail-339155-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","aging-related-biomarker-discovery-in-the-era-of-immune-checkpoint-inhibitors-for-cancer-patients","Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients","","Older cancer patients, especially those over 75, show worse clinical outcomes than younger groups due to age-related comorbidities, diminished immune function, and reduced tolerance to treatment adverse effects. In the immune checkpoint inhibitor (ICI) era, age is an important determinant of how predictive biomarkers for ICI respond are identified. Age-linked immune changes can alter tumor-infiltrating immune cells (TIICs), limiting immunotherapy effectiveness.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/aging-related-biomarker-discovery-in-the-era-of-immune-checkpoint-inhibitors-for-cancer-patients/339155/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/aging-related-biomarker-discovery-in-the-era-of-immune-checkpoint-inhibitors-for-cancer-patients/339155.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why do older cancer patients often have poorer outcomes?","Question",{"text":112,"@type":113},"Older patients frequently face worse outcomes because of age-related comorbidities, weakened immune function, and lower tolerance for treatment-related adverse effects.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does age influence predictive biomarker discovery in the ICI era?",{"text":117,"@type":113},"Age affects the discovery and performance of predictive biomarkers for ICI by shaping age-linked immune changes that alter tumor-infiltrating immune cells and immune cell function.",{"name":119,"@type":110,"acceptedAnswer":120},"What role do tumor-infiltrating immune cells (TIICs) play in ICI response?",{"text":121,"@type":113},"TIICs are crucial for cancer response. Age-related immune senescence can reduce TIIC infiltration and impair T cell function, which can limit the effectiveness of cancer immunotherapies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339155,1790518623,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","TYPE Review  \nPUBLISHED 15 March 2024  \nDOI 10.3389/fimmu.2024.1348189  \nOPEN ACCESS  \nEDITED BY  \nMohd Wajid Ali Khan, University of Hail, Saudi Arabia  \nREVIEWED BY  \nSubhash Kumar Tripathi,  \nSeattle Children’s Research Institute, United States  \nSaravanan Rajendrasozhan, University of Hail, Saudi Arabia  \n*CORRESPONDENCE Deyong Yang  \n[yangdeyong@dmu.edu.cn](yangdeyong@dmu.edu.cn)[ ](yangdeyong@dmu.edu.cn)Jianjun Zhang  \n[jzhang20@mdanderson.org](jzhang20@mdanderson.org)[ ](jzhang20@mdanderson.org)Shujing Wang  \n [wangshujing@dmu.edu.cn](wangshujing@dmu.edu.cn)  \n†These authors have contributed equally to this work  \nRECEIVED 02 December 2023  \nACCEPTED 29 January 2024  \nPUBLISHED 15 March 2024  \nCITATION  \nAl-Danakh A, Saﬁ M, Jian Y, Yang L, Zhu X, Chen Q, Yang K, Wang S, Zhang J and Yang D (2024) Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients.  \nFront. Immunol. 15:1348189 .  \ndoi: 10.3389/fimmu.2024.1348189  \nCOPYRIGHT  \n© 2024 Al-Danakh, Saﬁ, Jian, Yang, Zhu, Chen, Yang, Wang, Zhang and Yang. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients  \nAbdullah Al-Danakh 1†, Mohammed Saﬁ2†, Yuli Jian 3†, Linlin Yang 1†, Xinqing Zhu 1, Qiwei Chen 1, Kangkang Yang 4, Shujing Wang 3*, Jianjun Zhang 2* and Deyong Yang 1,5*  \n1 Department of Urology, First Afﬁliated Hospital of Dalian Medical University, Dalian, Liaoning, China, 2 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States, 3 Department of Biochemistry and Molecular Biology, Institute of Glycobiology, Dalian Medical University, Dalian, China, 4 Institute for Genome Engineered Animal Models of Human Diseases, National Center of Genetically Engineered Animal Models for International Research, Dalian Medical University, Dalian, Liaoning, China, 5 Department of Surgery, Healinghands Clinic, Dalian, Liaoning, China  \nOlder patients with cancer, particularly those over 75 years of age, often experience poorer clinical outcomes compared to younger patients. This can be attributed to age-related comorbidities, weakened immune function, and reduced tolerance to treatment-related adverse effects. In the immune checkpoint inhibitors (ICI) era, age has emerged as an inﬂuential factor impacting the discovery of predictive biomarkers for ICI treatment. These agelinked changes in the immune system can inﬂuence the composition and functionality of tumor-inﬁltrating immune cells (TIICs) that play a crucial role in the cancer response. Older patients may have lower levels ofTIICs inﬁltration due to age-related immune senescence particularly T cell function, which can limit the effectivity of cancer immunotherapies. Furthermore, age-related immune dysregulation increases the exhaustion of immune cells, characterized by the dysregulation of ICI-related biomarkers and a dampened response to ICI. Our review aims to provide a comprehensive understanding of the mechanisms that contribute to the impact of age on ICI-related biomarkers and ICI response. Understanding these mechanisms will facilitate the development of treatment approaches tailored to elderly individuals with cancer.  \nKEYWORDS  \naging, immunosenescence, neoplasm, immune biomarkers, immune checkpoint inhibitors  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nAs life expectancy has increased, geriatric oncology is becoming more critical due to the ever-increasing number of older cance","cbCaioRF2RnhpU1T","https://ap.wps.com/l/cbCaioRF2RnhpU1T","pdf",8428396,21,"English","# Key background\n## Aging and immunosenescence in cancer\n## Immune checkpoint biology and ICI mechanism\n# Review focus and objectives\n## Mechanisms linking age to ICI biomarkers and response","[{\"question\":\"Why do older cancer patients often have poorer outcomes?\",\"answer\":\"Older patients frequently face worse outcomes because of age-related comorbidities, weakened immune function, and lower tolerance for treatment-related adverse effects.\"},{\"question\":\"How does age influence predictive biomarker discovery in the ICI era?\",\"answer\":\"Age affects the discovery and performance of predictive biomarkers for ICI by shaping age-linked immune changes that alter tumor-infiltrating immune cells and immune cell function.\"},{\"question\":\"What role do tumor-infiltrating immune cells (TIICs) play in ICI response?\",\"answer\":\"TIICs are crucial for cancer response. Age-related immune senescence can reduce TIIC infiltration and impair T cell function, which can limit the effectiveness of cancer immunotherapies.\"}]","Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients | PDF",1790028286,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3fc8e0186eca85a6b6372ec5b3df9cd8.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e8433339e8a8489d7a638a19743dfe3.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df6b2105c93d39359ed088bae074b519.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2ccd5a0c90085493681227f44477261.webp",980,1385]